Hematology Frontier

As targeted therapies continue to transform the treatment landscape of chronic lymphocytic leukemia (CLL), therapeutic goals are evolving beyond long-term disease control toward deeper remissions, fixed-duration treatment strategies, and even the possibility of functional cure. At EHA 2026, several landmark studies provided important evidence supporting this paradigm shift.

Treatment options remain extremely limited for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who relapse after CD7 CAR-T therapy. Although previous studies of humanized CD5 CAR-T cells demonstrated encouraging antitumor activity, long-term follow-up revealed a significant safety challenge: a high incidence of severe and sometimes fatal infections.

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal subtype of DLBCL characterized by unique clinicopathological features and an increased risk of central nervous system (CNS) relapse. Due to its low incidence, comprehensive investigations into its biological characteristics have remained limited.

Complement C5 inhibitors have transformed the management of paroxysmal nocturnal hemoglobinuria (PNH) and remain the current standard first-line therapy. However, despite effective control of intravascular hemolysis, many patients continue to experience persistent anemia, limited hemoglobin recovery, and clinically significant extravascular hemolysis, leaving substantial unmet medical needs.

At the highly anticipated Plenary Session of the 2026 European Hematology Association (EHA) Congress, Professor Yizhen Li from the Children's Hospital of Soochow University presented his team’s original research findings.

Refractory immune thrombocytopenia (ITP) remains a major clinical challenge. Characterized by frequent relapses, chronic treatment dependence, and limited curative options, many patients struggle to achieve durable remission despite multiple lines of therapy.

At the 2026 European Hematology Association (EHA) Congress, the team led by Director Zhihui Li from Beijing GoBroad Boren Hospital presented two studies selected for poster presentation.

At the 2026 European Hematology Association (EHA) Congress, the field of cellular therapy witnessed a landmark breakthrough. During a prestigious Late-Breaking Oral Session, Professor Lei Fan from Jiangsu Provincial People's Hospital presented the first-ever clinical proof-of-concept data for LB2501, the world's first in vivo CD19/CD20 dual-target CAR-T therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

The 2026 European Hematology Association (EHA 2026) Congress was held in Stockholm, Sweden, from June 11–14, 2026. Dr. Yajing Zhang and colleagues from Beijing GoBroad Boren Hospital presented three studies at this year's meeting, focusing on two critical questions in the management of relapsed/refractory hematologic malignancies.

At the 2026 European Hematology Association (EHA) Congress, the team led by Professor Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented an impressive portfolio of 27 research studies spanning multiple dimensions of hematopoietic stem cell transplantation (HSCT).